Mectizan Expert Committee Statement on Mectizan Use During the COVID-19 Pandemic
29 January 2021
A Mectizan Expert Committee (MEC) Statement on the use of Mectizan® during the COVID-19 pandemic:
The MEC reminds country partners that Mectizan is donated only for the elimination of onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis).
The COVID-19 pandemic has brought interest from the media and an increase in publications on the action of ivermectin on SARS-Cov-2 viral replication. While we recognize the importance of COVID-19 interventions, Mectizan is donated strictly and solely for onchocerciasis and lymphatic filariasis elimination in the 50 endemic partner countries that have applied and been approved for Mectizan by the MEC. Merck & Co., Inc.* manufactures Mectizan, and Mectizan is approved for use, in the appropriate dose, specifically for the treatment of onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis).
The Mectizan Donation Program provides treatments with the clear understanding that donated Mectizan will only be used for these two diseases through mass drug distribution programs. Use of donated Mectizan for any other indication and at unauthorized doses is strictly prohibited and can be dangerous.
*MSD outside USA and Canada